Grepafloxacin

Grepafloxacin (OPC-17116) is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin has high tissue penetration and a promising pharmacodynamic profile[1][2][3].

Product Specifications

CAS Number

[119914-60-2]

Product Name Alternative

OPC-17116; dl-Grepafloxacin

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/grepafloxacin.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CN(C2CC2)C3=C(C(C)=C(F)C(N4CC(C)NCC4)=C3)C1=O)O

Molecular Formula

C19H22FN3O3

Molecular Weight

359.39

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Vacher S, et, al. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J Antimicrob Chemother. 1999 Nov;44 (5) :647-52.|[2]Owen K. Comparative grepafloxacin phototoxicity in mouse skin. J Antimicrob Chemother. 1998 Aug;42 (2) :261-4.|[3]Cynamon MH, et, al. The activity of grepafloxacin in two murine models of Mycobacterium avium infection. J Infect Chemother. 2004 Jun;10 (3) :185-8.|[4]Miyamoto H, et al. Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids. Bioorg Med Chem. 1995;3 (12) :1699-1706.